Daily Cosmetic Research Analysis
Three impactful studies span cosmetic safety, AI-enabled diagnosis, and exposure-related carcinogenesis. An outbreak investigation links iatrogenic botulism to unlicensed cosmetic botulinum products, a meta-analysis shows dermatoscopy-based deep learning outperforming clinicians for basal cell carcinoma detection, and a multicenter case-control study associates cosmetics-related chemical exposure with increased multiple myeloma risk.
Summary
Three impactful studies span cosmetic safety, AI-enabled diagnosis, and exposure-related carcinogenesis. An outbreak investigation links iatrogenic botulism to unlicensed cosmetic botulinum products, a meta-analysis shows dermatoscopy-based deep learning outperforming clinicians for basal cell carcinoma detection, and a multicenter case-control study associates cosmetics-related chemical exposure with increased multiple myeloma risk.
Research Themes
- Cosmetic procedure safety and regulation
- AI-assisted dermatologic diagnosis
- Environmental and occupational exposures in oncology
Selected Articles
1. A local outbreak of iatrogenic botulism associated with cosmetic injections of botulinum neurotoxin-containing products, England, 2025.
An outbreak investigation in North East England identified 25 iatrogenic botulism cases linked to cosmetic botulinum injections. Case-control analysis implicated two practitioners and an unlicensed product with mislabeled potency (370 vs 200 units/vial), underscoring urgent regulatory and pharmacovigilance needs.
Impact: Provides actionable epidemiologic evidence linking unlicensed cosmetic neurotoxin products to severe morbidity, with laboratory confirmation of potency discrepancies. Likely to influence regulation, clinical vigilance, and procurement practices.
Clinical Implications: Clinicians should suspect iatrogenic botulism in patients with recent cosmetic injections presenting with bulbar or autonomic symptoms, verify use of licensed products, report adverse events, and coordinate with public health. Procurement should avoid unlicensed products; counseling on risks is essential.
Key Findings
- 25 iatrogenic botulism cases occurred after cosmetic botulinum injections in North East England (June 2025).
- Case-control analysis associated cases with two practitioners and unlicensed products (p<0.001).
- Seized product testing found actual potency of 370 units/vial vs labeled 200 units/vial, indicating mislabeling and increased risk.
Methodological Strengths
- Use of a case-control design to identify risk factors during an outbreak.
- Laboratory confirmation of product potency discrepancies corroborating epidemiologic links.
Limitations
- Single-region outbreak with small case numbers limits generalizability.
- Control sample size and selection not fully detailed; potential recall and selection biases.
Future Directions: Implement standardized potency testing, traceability, and licensing verification; enhance adverse event reporting and surveillance; evaluate educational interventions for practitioners and consumers.
In June 2025, 25 botulism cases were identified among recipients of botulinum neurotoxin-containing cosmetic injections in North East England. A case-control study indicated that cases were more likely to have attended two specific practitioners and received an unlicensed product (p < 0.001). Testing of seized product detected a potency (370 units/vial) that was higher than listed on its labelling (200 units/vial). Strengthened regulation of cosmetic procedures is necessary for mitigating public health risks, which are exacerbated by the availability of unlicensed products.
2. Deep Learning Algorithms in the Diagnosis of Basal Cell Carcinoma Using Dermatoscopy: Systematic Review and Meta-Analysis.
Across 15 studies (internal n=32,069; external n=200), dermatoscopy-based deep learning achieved pooled sensitivity 0.96, specificity 0.98, and AUC 0.99, outperforming dermatologists on internal validation datasets. Retrospective designs, heterogeneous reference standards, and limited external validation constrain generalizability.
Impact: Synthesizes diagnostic accuracy of AI for BCC with rigorous meta-analytic methods and registration, offering quantitative benchmarks relative to clinician performance.
Clinical Implications: AI tools may assist triage and detection of BCC from dermatoscopy, potentially improving early diagnosis and workflow efficiency; however, deployment should be contingent on robust external validation and integration with clinical oversight.
Key Findings
- Pooled sensitivity 0.96 and specificity 0.98 for deep learning algorithms detecting BCC on dermatoscopy.
- AUC 0.99 for algorithms vs 0.96 for dermatologists on internal validation; difference significant (z=2.63; P=.008).
- Limited external validation (n=200) and heterogeneous reference standards limit generalizability.
Methodological Strengths
- PROSPERO-registered meta-analysis with bivariate random-effects modeling.
- Risk of bias assessed using a modified QUADAS-2 framework.
Limitations
- Predominantly retrospective primary studies with variable reference standards.
- Performance largely derived from internal validation; external validation sample was small.
Future Directions: Prospective, multi-center external validations with standardized reference standards and reporting (STARD/CONSORT-AI); evaluation of clinical utility and workflow integration.
BACKGROUND: In recent years, deep learning algorithms based on dermatoscopy have shown great potential in diagnosing basal cell carcinoma (BCC). However, the diagnostic performance of deep learning algorithms remains controversial. OBJECTIVE: This meta-analysis evaluates the diagnostic performance of deep learning algorithms based on dermatoscopy in detecting BCC. METHODS: An extensive search in PubMed, Embase, and Web of Science databases was conducted to locate pertinent studies published until November 4, 2024. This meta-analysis included articles that reported the diagnostic performance of deep learning algorithms based on dermatoscopy for detecting BCC. The quality and risk of bias in the included studies were assessed using the modified Quality Assessment of Diagnostic Accuracy Studies 2 tool. A bivariate random-effects model was used to calculate the pooled sensitivity and specificity, both with 95% CIs. RESULTS: Of the 1941 studies identified, 15 (0.77%) were included (internal validation sets of 32,069 patients or images; external validation sets of 200 patients or images). For dermatoscopy-based deep learning algorithms, the pooled sensitivity, specificity, and area under the curve (AUC) were 0.96 (95% CI 0.93-0.98), 0.98 (95% CI 0.96-0.99), and 0.99 (95% CI 0.98-1.00). For dermatologists' diagnoses, the sensitivity, specificity, and AUC were 0.75 (95% CI 0.66-0.82), 0.97 (95% CI 0.95-0.98), and 0.96 (95% CI 0.94-0.98). The results showed that dermatoscopy-based deep learning algorithms had a higher AUC than dermatologists' performance when using internal validation datasets (z=2.63; P=.008). CONCLUSIONS: This meta-analysis suggests that deep learning algorithms based on dermatoscopy exhibit strong diagnostic performance for detecting BCC. However, the retrospective design of many included studies and variations in reference standards may restrict the generalizability of these findings. The models evaluated in the included studies generally showed improved performance over that of dermatologists in classifying dermatoscopic images of BCC using internal validation datasets, highlighting their potential to support future diagnoses. However, performance on internal validation datasets does not necessarily translate well to external validation datasets. Additional external validation of these results is necessary to enhance the application of deep learning in dermatological diagnostics. TRIAL REGISTRATION: PROSPERO International Prospective Register of Systematic Reviews CRD42025633947; https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633947.
3. Environmental and occupational risk factors associated with multiple myeloma: a multicenter, hospital-based, matched case-control study.
In a multicenter matched case-control study (227 MM cases; 176 controls), cosmetics-related chemical exposure was associated with higher multiple myeloma odds (OR 2.85, 95% CI 1.56–5.21) and worse future perspective on QoL. Pesticides and organic solvents also influenced QoL domains, emphasizing modifiable occupational/environmental risks.
Impact: Identifies a significant association between cosmetics-related exposures and MM risk using a multicenter design and validated QoL measures, informing prevention strategies and exposure assessments.
Clinical Implications: Clinicians should incorporate detailed occupational/cosmetics exposure histories into MM risk assessment and survivorship care, counsel on exposure reduction, and collaborate with public health to guide workplace protections.
Key Findings
- Cosmetics-related chemical exposure associated with increased MM odds (OR 2.85; 95% CI 1.56–5.21).
- Exposure predicted higher disease symptoms and markedly worse future perspective on EORTC QLQ-MY20.
- Pesticides and organic solvents significantly impacted QoL domains, indicating broader exposure effects.
Methodological Strengths
- Multicenter, hospital-based matched case-control design with LASSO-adjusted multivariable models.
- Use of validated disease-specific QoL instrument (EORTC QLQ-MY20).
Limitations
- Exposure assessment relied on interviews and charts, subject to recall and misclassification biases.
- Generalizability limited to the West Bank context; causality cannot be inferred from observational design.
Future Directions: Prospective exposure quantification with biomarkers, replication in diverse populations, and intervention studies to reduce high-risk exposures in occupational settings.
INTRODUCTION: Multiple myeloma (MM), a hematologic malignancy driven by neoplastic plasma cell proliferation, remains insufficiently characterized with respect to occupational and environmental risk factors and their impact on patients' quality of life (QoL). This study explores modifiable exposures in the West Bank, Palestine, and evaluates their associations with MM risk and disease-specific QoL outcomes. METHODS: A multicenter, hospital-based case-control study was conducted between 2018 and 2025, including 227 MM patients and 176 matched controls. Matching was based on age, sex, hospital setting, and admission type. Occupational/environmental exposures including ionizing radiation, cosmetics-related agents, pesticides, organic solvents, and farming were assessed via structured interviews and chart reviews. MM diagnosis adhered to International Myeloma Working Group criteria. QoL was evaluated using the validated EORTC QLQ-MY20 instrument. Multivariable logistic and linear regression analyses were performed, adjusting for clinical confounders using LASSO selection. RESULTS: Cosmetics-related chemical exposure was independently associated with higher odds of MM (OR = 2.85; 95% CI: 1.56-5.21) and a mixed QoL profile. Specifically, it predicted increased disease symptoms (Coeff = 11.55; 95% CI: 2.82-20.28; p = 0.010), lower treatment side-effects scores (Coeff = -2.17; 95% CI: -8.57 to -0.23; p = 0.049), and a marked decline in future perspective (Coeff = -13.73; 95% CI: -22.88 to -4.58; p = 0.003). Pesticide exposure was significantly linked to lower disease symptom burden (Coeff = -3.77; 95% CI: -12.61 to -2.06; p = 0.041) and better future outlook (Coeff = 10.05; 95% CI: 0.77-19.34; p = 0.034). Meanwhile, organic solvent exposure (carcinogenic-organic compounds) was associated with a decline in future perspective (Coeff = -3.96; 95% CI: -5.70 to -2.62; p = 0.042). CONCLUSION: This study highlights cosmetics-related agents, pesticides, and organic solvents as key modifiable risk factors for both MM development and QoL deterioration. Their significant physical and psychological impacts underscore the urgency of integrating preventive occupational health strategies with holistic myeloma care that addresses symptom burden and future outlook.